Form 4: Akebia Therapeutics SVP, Chief Accounting Officer Executes Pre-Planned Stock Option Exercise and Sale

Richard C. Malabre, SVP and Chief Accounting Officer of Akebia Therapeutics, Inc., completed a pre-arranged exercise of stock options and subsequent sale of common stock totaling 15,000 shares on June 9, 2025, under a Rule 10b5-1 plan.

Summary

• Richard C. Malabre, Akebia Therapeutics' SVP, Chief Accounting Officer, exercised 15,000 stock options at an exercise price of $1.68 per share on June 9, 2025.
• Concurrently, Mr. Malabre sold 15,000 shares of common stock at a weighted average price of $4.01 per share on June 9, 2025.
• Both the option exercise and the stock sale were executed pursuant to a Rule 10b5-1 Non-Discretionary Option Exercise and Stock Sale Plan adopted by Mr. Malabre on December 12, 2024.
• Following these transactions, Mr. Malabre directly beneficially owns 266,914 shares of Akebia Therapeutics common stock.
• Mr. Malabre retains 321,000 unexercised stock options, which were granted as an inducement material to his employment and vest over four years, with 25% vesting on the first anniversary of the grant date and the remainder vesting in equal quarterly installments thereafter.

Sentiment

Score: 5

Explanation: The sentiment is neutral as this is a routine, pre-planned insider transaction under a Rule 10b5-1 plan, which is a common practice for executives managing their equity compensation. It does not reflect a specific positive or negative outlook on the company's performance.

Positives

• The sale price of $4.01 per share is significantly higher than the exercise price of $1.68 per share, indicating a profitable transaction for the reporting person.
• The transaction was conducted under a pre-arranged Rule 10b5-1 plan, which demonstrates a structured approach to managing equity compensation and mitigates concerns about opportunistic insider trading.

Negatives

• The sale of shares by a senior executive, even if pre-planned, can sometimes be perceived by the market as a lack of confidence, although this is often a routine part of executive compensation management.

Risks

• No specific new risks are introduced by this routine insider transaction; however, general market perception of insider selling, even under a 10b5-1 plan, could theoretically lead to minor, short-term sentiment shifts.

Future Outlook

The document indicates that the remaining 321,000 stock options held by the reporting person will continue to vest over four years, with 25% vesting on the first anniversary of the grant date and the remaining 75% vesting in equal quarterly installments thereafter, contingent on continued service.

Management Comments

• The stock option exercise and subsequent sale were made pursuant to a Rule 10b5-1 Non-Discretionary Option Exercise and Stock Sale Plan adopted by the reporting person on December 12, 2024.
• The options were granted by Akebia Therapeutics as an inducement material to the reporting person's entering into employment with the Issuer in accordance with Nasdaq Listing Rule 5635(c)(4).

Industry Context

Insider transactions, particularly those executed under Rule 10b5-1 plans, are a common practice in the biotechnology and pharmaceutical industries for executives to manage their equity compensation and liquidity needs. Such pre-planned sales are generally viewed as routine and less indicative of management's immediate outlook on the company's prospects compared to unplanned, discretionary sales.

Related Party Transactions

• The reported transactions involve an executive officer of Akebia Therapeutics, Richard C. Malabre, exercising stock options and selling shares, which are considered related party transactions in the context of insider dealings.

Stakeholder Impact

• Shareholders: The sale represents a minor dilution event if new shares were issued upon exercise, but primarily reflects an executive's planned liquidity event. Given it's a 10b5-1 plan, the impact on shareholder sentiment is typically minimal.
• Employees: No direct impact on employees is indicated by this filing.

Next Steps

• Continued vesting of the remaining 321,000 stock options held by Richard C. Malabre, with future quarterly vesting installments subject to his continued service.

Key Dates

Keywords

Akebia Therapeutics, AKBA, Form 4, Insider Transaction, Stock Option Exercise, Stock Sale, Rule 10b5-1 Plan, Beneficial Ownership, Chief Accounting Officer, Equity Compensation